Skip to content

Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients

Stage-specified Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Locoregionally-advanced Nasopharyngeal Carcinoma - A Retrospective, Population-based Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02604472
Enrollment
12206
Registered
2015-11-13
Start date
1998-01-31
Completion date
2015-10-31
Last updated
2015-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Neoplasm of Other Specified Site of Nasopharynx

Keywords

Nasopharyngeal carcinoma, induction chemotherapy, concurrent chemoradiotherapy

Brief summary

To investigate whether the additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) was able to improve overall survival (OS) and disease-free survival (DFS), and to clarify if stage-specified chemoradiotherapy regimens benefit the most for locoregionally advanced NPC.

Detailed description

Data of patients firstly diagnosed NPC from Jan 1st, 1998 to Jun 1st, 2013 were downloaded from Department of Medical Information, Sun Yat-Sen University Cancer Center. Patients were excluded if they had stage I or II disease, no complete medical records, received treatment previously, or without concurrent chemoradiotherapy. Follow-up data is updated on October 1st, 2015.The propensity score-matching (PSM) method was adopted to balance observed covariates between both groups. Propensity scores reflect the conditional probability that is intended to be uniform between patients received CCRT and IC+CCRT based on their baseline characteristics. Matching was performed based on nearest-neighbor matching, and comparing between CCRT and IC+CCRT patients were matched within their respective risk groups.

Interventions

OTHERCCRT

Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.

OTHERIC+CCRT

Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. firstly diagnosed NPC in SYSUCC from Jan 1st, 1998 to Jun 1st, 2013; 2. with complete medical records; 3. received radical RT.

Exclusion criteria

1. distant metastasis patients at first diagnosis, 2. recurrent patients, 3. not finishing radiotherapy, missing medical data, death during RT, stage I or II disease,received treatment previously, or without concurrent chemoradiotherapy were excluded.

Design outcomes

Primary

MeasureTime frame
overall survivalup to 10 years

Secondary

MeasureTime frame
disease-free survivalup to 10 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026